Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers.
Our lead investigational product
Our lead product is an investigational transdermal formulation of donepezil, the active ingredient in Aricept®. Donepezil is one of the most commonly prescribed treatments for the care of patients with Alzheimer’s disease. Corplex Donepezil is designed to provide sustained and controlled delivery of donepezil. It is being investigated as a once-weekly treatment for Alzheimer’s disease to deliver either 5 mg or 10 mg of donepezil per 24 hours over a one-week period, with a pharmacokinetic (PK) profile comparable to oral Aricept taken daily for seven days. Learn more
The safety and efficacy of Corplex Donepezil have not been established. There is no assurance that the product will receive health authority approval or become commercially available in any country.
Corium to lead commercialization activities for KP415
Investigational Product Candidate by KemPharm for Attention Deficit Hyperactivity Disorder (ADHD)
Corium will lead the commercialization efforts for KemPharm, Inc. (Nasdaq: KMPH) on their investigational product candidate, KP415, if approved. KP415 is indicated for the treatment of ADHD. It contains serdexmethylphenidate (SDX), the KemPharm product of d-methylphenidate (d-MPH). Read the press release about KP415